Fatty liver disease, also known as hepatic steatosis, occurs when excess fat accumulates within liver cells. It is one of the most common liver conditions worldwide — affecting approximately 25% of the global adult population — and its prevalence continues to rise in parallel with obesity and metabolic disease. Although many people with fatty liver have no symptoms, the condition can progress through inflammation and scarring to cirrhosis and liver failure if left unmanaged.
Fatty liver disease sits at the beginning of a progressive spectrum of liver injury. Unchecked inflammation in the more advanced steatohepatitis form can lead to cirrhosis — irreversible scarring that distorts liver architecture and impairs function — and eventually to portal hypertension and its complications. Patients with cirrhosis from fatty liver disease are also at elevated risk for hepatocellular carcinoma, even without first developing cirrhosis in some cases. MRI is uniquely positioned to noninvasively quantify liver fat and assess fibrosis stage — providing the information needed to stratify risk and monitor treatment without repeated liver biopsies.
Causes
Metabolic dysfunction.
The most common form is metabolic dysfunction-associated steatotic liver disease (MASLD) — previously called nonalcoholic fatty liver disease (NAFLD), with updated terminology adopted in 2023 to better reflect the underlying metabolic pathophysiology. MASLD is driven by insulin resistance, which causes the liver to accumulate excess triglycerides beyond its normal processing capacity. The condition is strongly associated with central (abdominal) obesity, type 2 diabetes, hypertriglyceridemia, low HDL cholesterol, and hypertension — collectively constituting metabolic syndrome. The liver in MASLD is not simply a passive repository of excess fat; the accumulated fat generates reactive oxygen species, activates inflammatory pathways, and in susceptible individuals triggers progressive hepatocyte injury, inflammation, and eventually fibrosis — a subset called metabolic dysfunction-associated steatohepatitis (MASH, previously NASH).
Other causes.
Alcohol-associated liver disease (ALD) produces identical histologic and imaging findings to MASLD through a different mechanism — ethanol metabolism generates toxic acetaldehyde and reactive oxygen species that directly injure hepatocytes and disrupt fat metabolism, resulting in hepatic steatosis, inflammation, and fibrosis. The two conditions can coexist. Less common causes of hepatic steatosis include rapid weight loss or prolonged fasting (which mobilizes peripheral fat into the liver), certain medications (corticosteroids, methotrexate, tamoxifen, amiodarone, valproic acid, and antiretroviral drugs), total parenteral nutrition, hypothyroidism, and rare inherited metabolic disorders including Wilson's disease and lipodystrophy syndromes.
Symptoms
The majority of patients with fatty liver disease are entirely asymptomatic — the condition is most commonly discovered incidentally when mildly elevated liver enzymes are found on routine blood work, or when hepatic echogenicity is noted on ultrasound performed for an unrelated indication. When symptoms do occur, they are nonspecific: fatigue, mild right upper quadrant discomfort or fullness, and occasionally nausea. The absence of symptoms does not indicate absence of significant disease — patients with advanced fibrosis (F3) from MASH may remain asymptomatic until they develop complications of cirrhosis including ascites, jaundice, gastrointestinal bleeding from varices, or hepatic encephalopathy. This silent course underscores the importance of proactive identification and staging in at-risk patients.
Diagnosis
Evaluation begins with liver function tests — ALT and AST are typically elevated in steatohepatitis but may be normal even in patients with significant fibrosis, limiting their diagnostic value. Non-invasive fibrosis scores including the FIB-4 index (calculated from age, AST, ALT, and platelet count) and the NAFLD fibrosis score help risk-stratify patients and identify those who need advanced imaging or biopsy. Ultrasound detects moderate to severe hepatic steatosis as increased liver echogenicity ("bright liver") but cannot quantify fat precisely or reliably detect early steatosis or fibrosis.
An MRI of the abdomen is the most accurate noninvasive method for liver assessment. MRI-PDFF (proton density fat fraction) — a specialized multi-echo chemical shift sequence — precisely quantifies the percentage of fat within the liver parenchyma, with measurements validated against liver biopsy and reproducible across different MRI systems. A PDFF above 5% defines hepatic steatosis; values above 17–22% indicate severe steatosis. This quantitative capability makes MRI-PDFF invaluable for monitoring treatment response — small but meaningful reductions in liver fat are detectable with MRI that cannot be seen on ultrasound. MR elastography (MRE) — in which acoustic waves are transmitted through the liver and their propagation measured by MRI — noninvasively measures liver stiffness, which correlates with fibrosis stage: values below 2.5 kPa are normal, 2.5–3.5 kPa suggest mild fibrosis, and above 4–5 kPa indicate advanced fibrosis or cirrhosis. Together, MRI-PDFF and MRE provide a comprehensive, biopsy-equivalent liver assessment that has transformed the management of fatty liver disease.
Classification
Fatty liver disease is categorized by the presence of inflammation and the degree of fibrosis, both of which determine prognosis and treatment urgency.
- Simple steatosis (MASLD without MASH): Fat accumulation without significant inflammation or hepatocyte injury. Lower risk of progression — less than 1–2% per year progress to advanced fibrosis. MRI-PDFF elevated; MRE stiffness normal or near-normal.
- Metabolic dysfunction-associated steatohepatitis (MASH): Fat accumulation plus active inflammation, hepatocyte ballooning, and lobular necrosis. Significantly higher risk of progression — up to 20–30% may develop advanced fibrosis over a decade. Elevated MRE stiffness; often requires biopsy for definitive staging.
- Fibrosis (F1–F3): Progressive scarring of the liver. Staged from mild perisinusoidal fibrosis (F1) to bridging fibrosis (F3). Risk of liver-related events rises substantially at F3. MRE stiffness increases progressively with fibrosis stage.
- Cirrhosis (F4): Advanced scarring with nodular regeneration and distorted liver architecture. Associated with portal hypertension, liver failure, and hepatocellular carcinoma risk. MRI shows nodular liver surface, heterogeneous parenchyma, and signs of portal hypertension.
Treatments
Treatment focuses on reversing the underlying metabolic drivers, halting fibrosis progression, and preventing the development of cirrhosis and its complications.
Lifestyle modification: Weight loss is the single most effective treatment for MASLD/MASH — a reduction of 5% of body weight reduces liver fat, 7–10% reduces steatohepatitis activity, and greater than 10% can improve fibrosis stage. A Mediterranean-style dietary pattern — rich in vegetables, whole grains, olive oil, and lean protein — has the strongest evidence for liver fat reduction. Reducing added sugars (particularly fructose) and refined carbohydrates is important, as these are preferentially converted to hepatic triglycerides. Regular aerobic exercise and resistance training independently reduce liver fat even without significant weight loss.
Management of metabolic comorbidities.
Optimizing control of type 2 diabetes, dyslipidemia, and hypertension is essential. GLP-1 receptor agonists (semaglutide, liraglutide) produce significant weight loss and directly reduce liver fat and MASH activity — semaglutide at the 2.4 mg weekly dose has demonstrated MASH resolution in 59% of patients in Phase 3 trials. SGLT-2 inhibitors (empagliflozin, dapagliflozin) reduce liver fat through weight loss and reduced hepatic gluconeogenesis. Bariatric surgery produces the most dramatic improvements in liver histology and can reverse even advanced fibrosis in appropriately selected patients.
Medications specifically approved for MASH.
Resmetirom — a thyroid hormone receptor-beta agonist — became the first FDA-approved medication specifically for MASH with moderate to advanced fibrosis in 2024, demonstrating both MASH resolution and fibrosis improvement in Phase 3 trials. Obeticholic acid and other FXR agonists, ACC inhibitors, and ASK-1 inhibitors are in late-stage development. The rapidly evolving treatment landscape makes specialist hepatology involvement important for patients with confirmed MASH and significant fibrosis.
Alcohol avoidance.
Complete elimination of alcohol is essential for all patients with hepatic steatosis — even modest alcohol intake amplifies liver injury, accelerates fibrosis progression, and substantially increases hepatocellular carcinoma risk in patients with underlying metabolic liver disease.
Monitoring.
Regular surveillance with liver enzymes, FIB-4 scoring, and periodic MRI-PDFF and MRE allows noninvasive tracking of treatment response and early detection of fibrosis progression — enabling timely escalation of therapy before irreversible cirrhosis develops.
Get an MRI to Confirm Your Diagnosis
Before surgical planning or starting treatment, a clear MRI diagnosis ensures the right path forward. First Look MRI offers self-pay Abdomen MRI scans — no doctor's order or insurance required — at our locations in Georgia, Texas, and Colorado.